Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Chief Scientific Officer | May 13, 2019 | May 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Milestone Pharmaceuticals Inc.
Report date May 13, 2019 · Filed May 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 43,392 |
Reported balance
After 2019-05-13 transaction · row 1
1 source rowRow 1 · 2019-05-13 · Conversion · Acquired 4,124 · Balance 43,392 F1: Each share of Class A-1 Preferred was convertible at any time, at the option of the holder, into Common Shares, on a one-for-one basis, had no expiration date and converted into Common Shares upon the closing of the Issuer's initial public offering. |
| Class A-1 PreferredSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-13 · Conversion · Disposed 4,124 · Balance 0 F1: Each share of Class A-1 Preferred was convertible at any time, at the option of the holder, into Common Shares, on a one-for-one basis, had no expiration date and converted into Common Shares upon the closing of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class A-1 Preferred was convertible at any time, at the option of the holder, into Common Shares, on a one-for-one basis, had no expiration date and converted into Common Shares upon the closing of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2019 Filed May 14, 2019 20:35 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | ConversionClass A-1 Preferred · Derivative | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029668 · doc4.xml · derivative · entry 2 Douville Philippe · CIK 0001771205 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,124 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class A-1 Preferred was convertible at any time, at the option of the holder, into Common Shares, on a one-for-one basis, had no expiration date and converted into Common Shares upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Class A-1 Preferred was convertible at any time, at the option of the holder, into Common Shares, on a one-for-one basis, had no expiration date and converted into Common Shares upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Class A-1 Preferred was convertible at any time, at the option of the holder, into Common Shares, on a one-for-one basis, had no expiration date and converted into Common Shares upon the closing of the Issuer's initial public offering. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:35 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | ConversionCommon Shares | 4,124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-029668 · doc4.xml · nonDerivative · entry 1 Douville Philippe · CIK 0001771205 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class A-1 Preferred was convertible at any time, at the option of the holder, into Common Shares, on a one-for-one basis, had no expiration date and converted into Common Shares upon the closing of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.